Skip to content

First ever inhalable ebola vaccine is successful in simian trials.

A collaborative team from The University of Texas and the National Institutes of Health have developed an inhalable vaccine that successfully protects primates against Ebola in simian trials. The team state that a needle-free, inhalable vaccine against Ebola presents certain advantages as it has been shown that this disease lines respiratory tract in infection, also, this will mean that immunization will not require trained medical personnel.  The opensource study is published in the Journal of Clinical Investigation.

Previous studies with primates suggest that aerosols of most biothreat agents, which are particles dispersed in the air, are infectious. Recent studies show that contact with the Ebola virus through the mucus membranes that line the respiratory tract results in infection, suggesting that airway linings may be important portals of entry for the virus. Aerosolized delivery has never before been tested for an Ebola vaccine or any other viral hemorrhagic fever vaccine.

The current study characterized the immune responses generated by vaccination against Ebola delivered to the respiratory tract as either an aerosol or liquid. Direct comparisons were made with an unrelated protective injectable Ebola vaccine. This included detailed comparisons between immune T cell responses in the lungs, spleen and blood. A single vaccination with the aerosol developed by the researchers protected non-human primates against the severe disease and death caused by lethal Ebola infection.

The team state that this study demonstrates successful aerosol vaccination against a viral hemorrhagic fever for the first time.  They go on to add that a single-dose aerosol vaccine would enable both prevention and containment of Ebola infections, in a natural outbreak setting where healthcare infrastructure is lacking or during bioterrorism and biological warfare scenarios.

The researchers surmise that the findings of this study provide the basis for advancing this experimental vaccine to an NIH phase I clinical study. They go on to conclude that in the future, pending approval through an Investigative New Drug Application, the aerosolized form of the vaccine will be evaluated for replication, safety and immunity development in a study in adults.

Source: The University of Texas Medical Branch


Researchers develop aerosolized vaccine that protects primates against Ebola - healthinnovations

Michelle Petersen View All

Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.

Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.